Estrella Immunopharma reports 10,000-fold reduction in leukemia burden in preclinical ARTEMIS studies
ESLA•
ESLA•Estrella Immunopharma reported a 10,000-fold reduction in leukemia burden in preclinical ARTEMIS studies. The company will present findings on December 12, 2026; clinical evaluation is needed to determine whether the results translate into improved patient outcomes.
ARTEMIS produced faster, deeper leukemia responses than conventional CAR-T cells in animal models, including complete regression of established disease outside bone marrow. The findings support development of lead candidate EB103, which is in the STARLIGHT-1 Phase I/II trial for B-cell non-Hodgkin lymphoma.
Estrella Immunopharma will present the preclinical findings at the American Society of Hematology meeting on December 12, 2026. Clinical evaluation is needed to determine whether the preclinical benefits translate into improved patient outcomes.